Khoja
Khoja v. Orexigen Therapeutics, Inc.
Opinion
Lead Opinion
Honsammartino, J.
ORDER: (1) GRANTING IN PART DEFENDANTS’ REQUEST FOR JUDICIAL NOTICE, (2) GRANTING DEFENDANTS’ MOTION TO DISMISS, AND (3) DISMISSING LEAD PLAINTIFF’S CONSOLIDATED COMPLAINT
(ECF No. 62)
Presently before the Court is Defendants Orexigen Therapeutics, Inc., Joseph P. Hagan, Michael A. Narachi, and Preston Klassen’s Motion to Dismiss ConsoÜ-dated Complaint for Violation of the Federal Securities Laws. (MTD, ECF No. 62.) Also before the Court are Lead Plaintiff Karim Khoja’s Opposition to (ECF No. 67) and Defendants’ Reply in Support of (ECF No. 69) the MTD, as well as Defendants’ Request for Judicial Notice (ECF No. 62-25) and Lead Plaintiff’s Objections to (ECF No. 68) and Defendants’ Reply in Support of (ECF No. 69-1) the RJN. 1 The Court vacated the hearing and took the matter under submission without oral argument pursuant to Civil Local Rule 7.1(d)(1). (ECF No. 70.) Having considered the parties’ arguments and the law, the Court GRANTS IN PART AND DENIES IN PART Defendants’ RJN (ECF No. 62-25), GRANTS Defendants’ MTD (ECF No. 62), and DISMISSES Lead Plaintiffs Consolidated Complaint (CC, ECF No. 55).